| Today’s Big NewsJun 5, 2025 |
| By Nick Paul Taylor RegenXBio has shared updated phase 1/2 data on its Duchenne muscular dystrophy (DMD) gene therapy, providing evidence that its pivotal dose improves functional outcomes in older boys with the disease. |
|
|
|
By James Waldron Cullinan Therapeutics is paying $20 million upfront for a BCMAxCD3 bispecific T-cell engager that the biotech plans to pair with its existing CD19 candidate. |
By Angus Liu As Merck & Co., Bristol Myers Squibb and Pfizer have hopped on the PD-(L)1xVEGF bispecific bandwagon, the question becomes how far the fanfare will spread. |
Sponsored by Thermo Fisher Scientific Austin Read of Thermo Fisher Scientific discusses how combining biospecimens with real-world data is advancing diagnostics, treatment and the future of patient care. |
|
From gene therapy pipelines to early-stage VC deals, biotech leaders are seeking clarity in the chaos. That’s why companies are sharing their insights through Fierce content hubs — with weekly features right here in your inbox. See how others are shaping the narrative. 
|
|
By James Waldron Corcept Therapeutics has tried to cast its recent phase 2 amyotrophic lateral sclerosis (ALS) failure in a more flattering light by pointing to promising survival data. |
Sponsored by Bayer Discover how Bayer and BlueRock are redefining biotech partnerships. From breakthrough Parkinson’s therapies to a unique “arm’s-length” model, this episode of The Top Line dives into what makes their collaboration a blueprint for the future. |
By Darren Incorvaia Rapt Therapeutics has conducted its second round of layoffs in just under a year, continuing a period of upheaval following the clinical hold—and eventual discontinuation—of the immunology biotech’s former lead asset. |
Sponsored by Marken, UPS Healthcare Precision Logistics Radiopharma is revolutionizing modern medicine. Discover how precision logistics empowers faster, safer delivery of life-impacting therapies when every second counts. |
By James Waldron Cough-focused biotech Seyltx has secured the option to license a portfolio of eight GluN2B antagonists from NeurOp, including one candidate that has completed a phase 1 trial. |
By Gabrielle Masson,Darren Incorvaia,James Waldron The Fierce Biotech Fundraising Tracker records venture capital rounds of $50 million or more secured by biotechs. |
By Kevin Dunleavy Bayer has taken another step toward achieving its €3 billion peak sales estimate for androgen receptor inhibitor Nubeqa, scoring an FDA approval to expand its use to all patients with metastatic castration-sensitive prostate cancer, with or without added chemotherapy. |
By Paige Minemyer UnitedHealth Group hosted a shareholder meeting earlier this week amid a series of financial challenges and negative headlines, and a FAQ document posted to its website Wednesday offers a look at the questioning that executives were bracing for. |
Fierce podcasts Don’t miss an episode |
| This week on "Podnosis," we’re examining the future of tech-enabled home care and the policy decisions that could determine whether these models become permanent fixtures in the U.S. healthcare system. |
|
|---|
|
|
Whitepaper We analyzed ~300 launches to identify the factors most correlated with commercial success & built a framework for peak go-to-market performance. Presented by Blue Matter, strategic consultants in the life sciences |
| The Lighthouse at Pier 61 in New York City |
|
|
| |
|
+(2)+(2).png)
